US FDA grants priority review for Opdivo plus Cabometyx for advanced RCC
Phase 3 CheckMate-9ER trial showed that Opdivo plus Cabometyx improved overall survival, progression-free survival and objective response rate
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Oct 20
Phase 3 CheckMate-9ER trial showed that Opdivo plus Cabometyx improved overall survival, progression-free survival and objective response rate
19 Oct 20
The US regulator approved Genentech’s Supplemental New Drug Applications for Venclexta plus azacitidine under its RTOR and Project…
16 Oct 20
The acquisition would add Disarm's axonal degeneration therapies to expand Lilly's pain and neurodegeneration capabilities
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Oct 20
Inmazeb comprises three monoclonal antibodies of similar structure, including atoltivimab, maftivimab and odesivimab-ebgn
12 Oct 20
C3G is a rare and severe primary glomerulonephritis, prevalent in adolescents and young adults, characterised by complement dysregulation
12 Oct 20
Zeposia met both primary and secondary efficacy endpoints in the clinical trial and showed statistically significant improvements
09 Oct 20
Takeda to make an upfront payment of $300m and up to $740m to Arrowhead as potential milestone payments
09 Oct 20
The agreement with EC has an option that enables EU Member States to secure up to additional 200…
08 Oct 20
The data from interim post-authorisation study showed an overall performance of 93.3% sensitivity and 98.4% specificity for ID…
08 Oct 20
Phase 3 AFFINE study is an open-label, multicentre, single-arm study, designed to evaluate the efficacy and safety of…